Many patients with diabetes develop numbness, tingling, pain, or weakness in their hands or feet, a condition called diabetic neuropathy which refers to symptoms and signs of neuropathy, or nerve damage, as a result of diabetes. There are many other reasons for nerves to be damaged or harmed. An important clue that often distinguishes this condition from other forms of neuropathy is that the nerve damage is symmetrical. This means the nerve damage is similar on both sides, for instance, both feet. If the nerve of only one side of the foot or arm is damaged, then the neuropathy is likely to be from another source, such as a nerve entrapment.
Neuropathic pain is the most common chronic complication of diabetes mellitus. The mechanisms involved in the development of diabetic neuropathy include changes in the blood vessels that supply the peripheral nerves; metabolic disorders, such as the enhanced activation of the polyol pathway; myo-inositol depletion; and increased non-enzymatic glycation.
Lifestyle changes, natural ways to have improvement
While good control
of blood sugar levels is known to lower the risk, there are other measures diabetes patients can take. In
particular, by maintaining a healthy weight, quitting smoking, and receiving
treatment for high blood pressure, those with diabetes may reduce the risk of
further deterioration and perhaps reversal with the use of natural remedies.
A low-fat vegan diet may lessen diabetic neuropathy pain – A low-fat vegan diet reduced symptoms of peripheral neuropathy among patients with type 2 diabetes in the randomized, controlled Dietary Intervention for Chronic Diabetic Neuropathy Pain (DINE) study, August 2014.
Natural diabetic neuropathy treatment, herbs, vitamins,
supplements, nutrients
Pharmaceutical medications for the treatment of
diabetic neuropathy don't seem to offer a cure for the condition. There are certain supplements that may play a role in
reducing the risk or severity of diabetic neuropathy and provide an alternative
diabetic neuropathy treatment. There's still much to be learned about the effectiveness of these
supplements in terms of diabetic neuropathy treatment, and if they do work, what dosages are ideal. In the meantime, if you
have diabetes or diabetic neuropathy, you may discuss with your doctor following
a healthy diet, and perhaps
the following herbal and nutritional options.
If your doctor decides to use more than one supplement at a time,
use lower dosages since combining them can cause side effects such as
overstimulation and insomnia. In fact, try one supplement at a time for a week
to become familiar with it before combining it with another supplement.
ALA
Q. Would lipoic acid be a good medication for painful non diabetic peripheral
neuropathy?
A. There have been a few studies that showed alpha
lipoic acid to be helpful in diabetic peripheral neuropathy, but I have not come
across studies evaluating alpha lipoic acid in non diabetic neuropathy.
Alpha lipoic
acid
is one if the most important nutrients to consider for diabetes.
Alpha Lipoic acid has
been evaluated for blood sugar control, and it may also be considered in diabetic neuropathy and kidney
disease. A dose of 50 mg daily appears to be appropriate
and a cautious way to begin treatment even though many studies have used much
higher dosages such as 300 to 1800 mg a day. Alpha lipoic acid is more effective when
treatment is started early before the diabetic neuropathy has progressed to a
late stage.
Neurosci Lett. 2015. Effects of prostaglandin E1 plus methylcobalamin alone and in combination with lipoic acid on nerve conduction velocity in patients with diabetic peripheral neuropathy: A meta-analysis. This report was to evaluate the efficacy of lipoic acid, prostaglandin E1 and methylcobalamin (L+P+M) for the treatment of diabetic peripheral neuropathy (DPN) in comparison with that of prostaglandin E1 plus methylcobalamin (P+M), in order to provide the basis and reference for clinical rational drug use. L+P+M therapy was superior to P+M therapy for improvement of clinical efficacy and NCVs in DPN patients.
Efficacy and safety of high-dose α-lipoic acid in the
treatment of diabetic polyneuropathy.
Zhonghua Yi Xue Za Zhi. 2010.
A total of 236 diabetics with symptomatic polyneuropathy were given α-lipoic
acid 1800 mg daily for 12 weeks. Results: 73% patients with symptomatic
polyneuropathy improved after treatment versus 18% with placebo. Individual
symptom scores of pain, extremity numbness, burning sensation or resting
abnormal sensations were significantly diminished as compared to those before
treatment and placebo group. Nerve conduction velocity had no change. HbA1c
further decreased at the end of trial. The incidence rates of adverse effects
were 25% vs 11% in the treatment and control groups. The major manifestation was
burning sensation from throat to stomach.
Comments: 1800 mg is a very high dose, most patients may with to
start with 50 mg a day of R alpha lipoic acid and gradually increase if no
untoward reactions occur.
Alpha-lipoic acid may improve symptomatic diabetic polyneuropathy.
Neurologist. 2007. Tang J, Wingerchuk DM, Crum BA, Rubin DI,
Demaerschalk BM. Department of Neurology, Mayo Clinic Rochester, Rochester, MN,
USA.
Oral alpha lipoic acid may improve neuropathic symptoms in diabetic distal
symmetric polyneuropathy. A single modestly valid RCT demonstrated that 600 mg
was an effective and well-tolerated dose.
Comments: For long term use, I think a much lower dose is
appropriate, perhaps 50 mg or R lipoic acid.
Oral treatment with alpha-lipoic acid improves symptomatic diabetic
polyneuropathy: the SYDNEY 2 trial.
Diabetes Care. 2006. FRCPE, Deutsche Diabetes-Klinik,
Deutsches Diabetes-Zentrum, Leibniz-Institut an der Heinrich-Heine-Universitat,
Auf'm Hennekamp 65, 40225 Dusseldorf, Germany.
The aim of this trial was to evaluate the effects of alpha lipoic acid (ALA) on
positive sensory symptoms and neuropathic deficits in diabetic patients with
distal symmetric polyneuropathy (DSP). In this multicenter, randomized,
double-blind, placebo-controlled trial, 181 diabetic patients in Russia and
Israel received once-daily oral doses of 600 mg (ALA600), 1,200 mg (ALA1200),
and 1,800 mg (ALA1800) of ALA or placebo for 5
weeks after a 1-week placebo run-in period. The primary outcome measure was the
change from baseline of the Total Symptom Score (TSS), including stabbing pain,
burning pain, paresthesia, and asleep numbness of the feet. Secondary end points
included individual symptoms of TSS, Neuropathy Symptoms and Change (NSC) score,
Neuropathy Impairment Score (NIS), and patients' global assessment of efficacy.
Oral treatment with alpha lipoic acid for 5 weeks
improved neuropathic symptoms and deficits in patients with DSP. An oral dose of
600 mg once daily appears to provide the optimum risk-to-benefit ratio.
Alpha lipoic
acid or Gabapentin?
Switching from pathogenetic treatment with alpha-lipoic acid to gabapentin and
other analgesics in painful diabetic neuropathy: a real-world study in
outpatients.
J Diabetes Complications. 2008. Ruessmann HJ; on behalf of the German
Society of out patient diabetes centres AND (Arbeitsgemeinschaft
niedergelassener diabetologisch tätiger Ärzte e.V.). Heinz-Jürgen Ruessmann,
President AND, Wilhelminenstr, Dinslaken, Germany.
In this retrospective real-world study, we aimed to evaluate whether switching
from the treatment option alpha-lipoic acid to drugs for symptomatic treatment
of diabetic neuropathic pain such as gabapentin would be associated with changes
in efficacy, safety, and cost-effectiveness. A cohort of 443 diabetic patients
with chronic painful diabetic neuropathy were treated with alpha-lipoic acid 600
mg qd orally for a mean period of 5 years. After stopping this treatment, 293
patients were switched to gabapentin (600-2400 mg/day), while 150 patients
remained untreated because of no acute symptoms. In the untreated group, 110
(73%) patients developed neuropathic symptoms as soon as 2 weeks after the end
of treatment with alpha-lipoic acid. In the group started on gabapentin, 131
(45%) patients had to stop taking the drug due to intolerable side effects.
Among the patients treated with gabapentin 132 (45%) were responders on an
average dose of 1200 mg/day, whereas 161 (55%) were nonresponders at gabapentin
doses up to 2400 mg/day. These patients required an alternative treatment which
consisted of pregabalin, carbamazepine, amitriptyline, tramadol, or morphine as
monotherapy or in combination. The daily costs for alpha-lipoic acid were
considerably lower than those for gabapentin or several frequently used drug
combinations. In conclusion, switching from long-term treatment with alpha-lipoic
acid to central analgesic drugs such as gabapentin in painful diabetic
neuropathy was associated with considerably higher rates of side effects,
frequencies of outpatient visits, and daily costs of treatment.
Acetyl-L-carnitine
is helpful in the treatment of diabetic neuropathy.
An
Acetyl l-carnitine dose of 100 to 300 mg a
few times a week may be tried. Higher doses can cause overstimulation.
Occasionally carnitine may also be tried.
Role of
acetyl-L-carnitine in the treatment of
diabetic peripheral neuropathy.
Ann Pharmacother. 2008. Evans JD, Jacobs TF, Evans EW.
Department of Clinical and Administrative Sciences, College of Pharmacy,
University of Louisiana at Monroe, Monroe, LA, USA.
A MEDLINE search of the English-language literature was
performed using the search terms carnitine, diabetes, nerve, and neuropathy.
Studies identified were then cross-referenced for their citations. The search
was limited to clinical trials, meta-analyses, and reviews addressing the use of
acetyl-L-carnitine
for the treatment of diabetic peripheral neuropathy.
Studies that included other disease states that could cause peripheral
neuropathy were excluded. Two large clinical studies that used
acetyl-L-carnitine
for the treatment of diabetic peripheral neuropathy
were identified. The results from 2 published clinical trials involving 1679
subjects were included. Subjects who received at least 2 g daily of
acetyl-L-carnitine
showed decreases in pain scores. One study showed
improvements in electrophysiologic factors such as nerve conduction velocities,
while the other did not. Patients who had neuropathic pain reported reductions
in pain using a visual analog scale. Nerve regeneration was documented in one
trial. Data on treatment of diabetic peripheral neuropathy with
acetyl-L-carnitine
support its use.
Acetyl-L-carnitine improves pain, nerve regeneration, and vibratory
perception in patients with chronic diabetic neuropathy: an analysis of two
randomized placebo-controlled trials.
Diabetes Care. 2005. Sima AA, Calvani M, Mehra M, Amato A;
Acetyl-L-Carnitine Study Group. Department of Pathology, Wayne State University
School of Medicine, Detroit, Michigan
We evaluated frozen databases from two 52-week randomized placebo-controlled
clinical diabetic neuropathy trials testing two doses of acetyl-L-carnitine (ALC):
500 and 1,000 mg/day t.i.d. Intention-to-treat
patients amounted to 1,257 or 93% of enrolled patients. Efficacy end points were sural nerve morphometry, nerve conduction velocities, vibration perception
thresholds, clinical symptom scores, and a visual analogue scale for most
bothersome symptom, most notably pain. The two studies were evaluated separately
and combined. Data showed significant improvements in sural nerve fiber
numbers and regenerating nerve fiber clusters. Nerve conduction velocities and
amplitudes did not improve, whereas vibration perception improved in both
studies. Pain as the most bothersome symptom showed significant improvement in
one study and in the combined cohort taking 1,000 mg ALC. These
studies demonstrate that ALC treatment is efficacious in alleviating symptoms,
particularly pain, and improves nerve fiber regeneration and vibration
perception in patients with established diabetic neuropathy and may provide an
alternative diabetic neuropathy treatment.
Acetyl-L-carnitine in the treatment of diabetic
neuropathy. A long-term, randomized, double-blind, placebo-controlled study.
Drugs R D. 2002.
De Grandis D, Minardi C. Department of
Neuroscience, Ospedale Civile, Rovigo, Italy.
To assess the efficacy and tolerability of acetylcarnitine versus
placebo in the treatment of diabetic neuropathy, mainly by evaluating the
effects of treatment on electrophysiological parameters and pain symptoms.
This was a multicentre, randomised, double-blind,
placebo-controlled, parallel-group study. 333 patients meeting
clinical and/or neurophysiological criteria for diabetic neuropathy were
enrolled. Patients were randomised to treatment with acetyl-L-carnitine
or placebo. Acetylcarnitine (or placebo) was started intramuscularly at a dosage
of 1000 mg/day for 10 days and continued orally at a dosage of 2000 mg/day for
the remainder of the study (355 days). The
main efficacy parameter was the effect of treatment on 6- and 12-month changes
from baseline in nerve conduction velocity (NCV) and amplitude in the sensory (ulnar,
sural and median) and motor (median, ulnar and peroneal) nerves. The effect of
treatment on pain was also evaluated by means of a visual analogue scale (VAS).
Among the 294 patients with impaired electrophysiological parameters at
baseline, those treated with LAC showed a statistically significant improvement
in mean NCV and amplitude compared with placebo. The greatest changes
in NCV (at 12 months) were observed in the sensory sural nerve (7 m/sec in the
acetylcarnitine group vs +1.0 m/sec in the placebo group), sensory ulnar nerve and motor peroneal
nerve, whereas the greatest changes in amplitude were recorded in the motor peroneal
nerve. After 12 months of treatment, mean VAS scores
for pain were significantly reduced from baseline by 39% in acetylcarnitine-treated
patients compared with 8% in placebo recipients. acetylcarnitine was well tolerated over the study period. Acetylcarnitine was effective and well tolerated in improving neurophysiological
parameters and in reducing pain over a 1-year period. acetylcarnitine is,
therefore, a promising treatment option in patients with diabetic neuropathy.
Carnosine supplementation
Sci Rep. 2017. Carnosine Attenuates the Development of both Type 2 Diabetes and
Diabetic Nephropathy in BTBR ob/ob Mice. Carnosine could be a novel therapeutic
strategy to treat patients with DN and/or be used to prevent DN in patients with
diabetes.
Benfotiamine has been
evaluated in diabetic neuropathy with positive results.
Testimonial received by email in 2016
I am a type 2 Diabetic and have had problems with numbness and no feeling in
part of both feet. I have been taking Benfotiamine 150 mg 3 time a day for about
2 months. I can tell a difference now. I use to not be able to walk barefoot in
the house due to pain. All that is gone and walking on floor bare foot now
doesn't bother me.
B vitamins could be helpful, perhaps combined with gabapentin (Neurotin). Vitamin B12 is a possible supplement to take for diabetic neuropathy.
Vitamin B12 may be more effective than nortriptyline in
improving painful diabetic neuropathy.
Int J Food Sci Nutr. 2009. Talaei A, Siavash M, Majidi H, Chehrei A.
Department of Endocrinology, Arak University of Medical Sciences, Arak, Iran.
In this randomized, single-blind clinical trial we compared the efficacy of
parenteral vitamin B12 and nortriptyline, for symptomatic improvement of pain,
paresthesia, burning, freezing, stabbing and electrical sensation. One hundred
patients (50 in each group) completed the study. After treatment, the pain score
based on a visual analogue scale decreased 3.66 units in the vitamin B(12) group
and 0.84 units in the nortriptyline group. Similarly, the paresthesia score
decreased 2.98 units versus 1.06 units. Changes in vibration, position, pinprick
and nerve conduction parameters were not significant in two groups. Vitamin B12
is more effective than nortriptyline for the treatment of symptomatic painful
diabetic neuropathy.
Curr Med Res Opin. 2015. Nutritional management of patients with diabetic peripheral neuropathy with L-methylfolate-methylcobalamin-pyridoxal-5-phosphate: results of a real-world patient experience trial. This study assessed changes in symptoms and quality of life in patients taking a novel prescription medical food, L-methylfolate-methylcobalamin-pyridoxal-5-phosphate (LMF-MC-PP, Metanx ), intended to address the underlying metabolic needs of patients with diabetic peripheral neuropathy.R A total of 544 patients participated in the study. Patients reported a mean reduction of 35% in NTSS-6 scores from after 12 weeks on LMF-MC-PP. Mean (standard deviation) score was reduced by 1.5 (1.8) at 12 weeks from a baseline of 4.3 (1.5). Patients achieved significant reductions in self-reported disruptions in work/school activities, social life, and family life, respectively. Overall pain rating decreased by 32%. Patients previously treated with medications reported a 52% improvement in medication satisfaction. In a real-world clinical setting, patients with diabetic peripheral neuropathy treated with LMF-MC-PP achieved significant improvements in total symptom score (NTSS-6) and in quality of life and functioning, together with greater medication satisfaction.
Treatment of peripheral diabetic neuropathic pain with
gabapentin alone or combined with vitamin B complex. preliminary results.
Proc West Pharmacol Soc. 2004.
Neuropathic pain is a syndrome that affects around 1% of population. This
condition can be severely disabling and traditional analgesics are sometimes
useless against this type of pain. Several adjuvants such as the anticonvulsive
agent gabapentin - Neurontin - have been used to treat diabetic neuropathy with
several degrees of effectiveness, but it is characterized of a high incidence of
dizziness, somnolence and ataxia. Previously we have found a functional
synergistic interaction after co-administration of gabapentin and B vitamins by
using a neuropathic pain model in the rat. In order to evaluate the efficacy of
gabapentin and B vitamins in the treatment of diabetic neuropathy in humans we
carried out a comparative trial. In this study are presented preliminary results
from 6 patients assigned to two groups: group A (n=3) received gabapentin, and
group B (n=3) received gabapentin plus B vitamins. In both groups, the dose was
increased at weekly intervals, and characteristics of pain and some parameters
of quality of life were assessed. Both treatments significantly reduced pain and
improved quality of life in the patients. Dizziness was the main adverse event
observed in both groups. Data suggest that the combination of gabapentin and B
vitamins could be an alternative treatment for diabetic neuropathic patients.
Ginkgo biloba herbal extract - Dr. Susanne Koeppen, from the University of Essen in Germany, and colleagues randomly assigned 60 diabetic patients with neuropathy to ginkgo biloba extract, folate, both agents, or placebo. All three active treatments were superior to placebo, with the best effect seen with the combination of folate and ginkgo biloba extract.
St. John's Wort seed and feverfew flower extracts
Fitoterapia. 2014 Jan. St. John's Wort seed and feverfew flower extracts
relieve painful diabetic neuropathy in a rat model of diabetes. Painful diabetic
peripheral neuropathy (DPN) is a common complication of diabetes and the few
approved therapies for the management of pain have limited efficacy and side
effects. With the aim to explore and develop new pharmacological treatments, we
investigated the antihyperalgesic properties of St. John's Wort (SJW) and
feverfew in streptozotocin (STZ)-diabetic rats. Acute administration of a SJW
seed extract reversed mechanical hyperalgesia with a prolonged effect. A SJW
extract obtained from the aerial portion of the plant and a feverfew flower
extract partially relieved neuropathic pain whereas a feverfew leaf extract was
ineffective. The antihyperalgesic efficacy of these herbal drugs was comparable
to that of clinically used antihyperalgesic drugs (carbamazepine, lamotrigine,
l-acetyl-levocarnitine). Further examinations of SJW and feverfew composition
revealed that hyperforin and hypericin might be responsible for the
antihyperalgesic properties of SJW whereas the efficacy of feverfew seems to be
related to the presence of parthenolide. Rats undergoing treatment with SJW and
feverfew did not show any behavioral side effect or sign of altered locomotor
activity. Our results suggest that SJW and feverfew extracts may become new
therapeutic perspectives for painful DPN.
Symptoms and signs
The symptoms of diabetic neuropathy are many. Some of the earliest
symptoms include numbness and tingling in feet. Strangely, some people notice
few or no symptoms, while others are significantly disabled. Symptoms of
diabetic neuropathy are sometime mild in the beginning, and since the damage to
nerves occurs over a period of several years, mild cases may go unnoticed for a
long time. Additional diabetic neuropathy symptoms include abnormal sensations
in the hands and feet, diarrhea, constipation, vertigo or dizziness, and
impotence. Impotence occurs because the nerves supplying the penis become numb.
Types of diabetic neuropathy
Doctors classify diabetic neuropathy into four categories: peripheral,
autonomic, focal, proximal, and peripheral since the nerve damage in each region
causes different symptoms.
Autonomic neuropathy causes changes in digestion, bowel
and bladder function, sexual response, and perspiration. It can also affect the
nerves that serve the heart and control blood pressure. Autonomic neuropathy
leads to gastrointestinal symptoms of diarrhea or constipation.
Focal neuropathy is due to the sudden weakness of one
nerve, or a group of nerves acting in a specific area, causing muscle weakness
or pain. Any nerve in the body may be affected.
Proximal neuropathy causes pain in the thighs, hips, or
buttocks and leads to weakness in the legs. Contrast this with peripheral
diabetic neuropathy which causes either pain or loss of feeling in the toes,
feet, legs, hands, and arms. Peripheral diabetic neuropathy pain can be managed
by pain medicines and other drugs.
Treatment of diabetic neuropathy
pain, traditional medical
The traditional treatment for diabetic neuropathy pain is with
analgesics, non-steroidal anti-inflammatory drugs such as ibuprofen or naproxyn,
antidepressants, and anticonvulsants. The treatment of autonomic neuropathy is
symptomatic. A new treatment for diabetic neuropathy is a drug called
Lyrica.
There are several conditions besides diabetes that can
cause neuropathic pain. Neuropathic pain may be caused by abnormalities of
structural lesions in the peripheral or central nervous system. Many common
diseases, such as postherpetic neuralgia, trigeminal neuralgia, spinal cord
injury, cancer, stroke, and degenerative neurological diseases may produce
neuropathic pain.
Medication and
drugs prescribed for this condition
Pain modulation is a key treatment goal for diabetic peripheral neuropathy
patients. Guidelines have recommended antidepressant, anticonvulsant, analgesic,
and topical medications-both approved and off-label-to reduce pain in this
population.
Treatment of peripheral diabetic neuropathic pain with medicine is
evolving. Various drugs have been tried and recently gabapentin ( Neurontin )
and morphine combined have lead to better analgesia at lower doses of each drug
than either as a single agent, with constipation, sedation, and dry mouth as the
most frequent adverse effects.
Pregabalin ( Lyrica, Pfizer ) is a GABA analog with
similar structure and actions to gabapentin. It has antiepileptic, analgesic and
anxiolytic activity. Pregabalin is indicated for the management of neuropathic
pain associated with diabetic neuropathy and post-herpetic neuralgia.
Medical treatment for pain
Ther Adv Chronic Dis. 2015.Treatment of painful diabetic neuropathy. Painful
diabetic neuropathy (PDN) is a debilitating consequence of diabetes that may be
present in as many as one in five patients with diabetes. The objective
assessment of PDN is difficult, making it challenging to diagnose and assess in
both clinical practice and clinical trials. No single treatment exists to
prevent or reverse neuropathic changes or to provide total pain relief.
Treatment of PDN is based on three major approaches: intensive glycemic control
and risk factor management, treatments based on pathogenetic mechanisms, and
symptomatic pain management. Clinical guidelines recommend pain relief in PDN
through the use of antidepressants such as amitriptyline and duloxetine, the γ-aminobutyric
acid analogues gabapentin and pregabalin, opioids and topical agents such as
capsaicin.
Intensive insulin therapy
Several years after participating in a clinical trial of
intensive diabetes therapy, patients assigned this treatment still showed
improvements in neuropathy symptoms. The study involved 1,257 subjects who were
enrolled in the Diabetes Control and Complications Trial who were randomly
assigned to receive intensive or conventional diabetes therapy. The intensive
approach involved at least three injections of
insulin per day, while the
conventional approach involved no more than two. After being followed for an
average of 6.5 years, all of the subjects were encouraged to use the intensive
therapy. The patients were then evaluated annually for neuropathy and other
complications.The group initially assigned to receive intensive therapy had a
lower prevalence of neuropathy than those who began with conventional therapy:
17 percent vs. 28 percent. Signs and symptoms of diabetic neuropathy were also
less common in the first intensive therapy group, even though patients' blood
sugar levels were comparable to those seen in the conventional therapy group.
The relationship between blood sugar control and neuropathy suggests that
intensive therapy has a durable effect on neuropathy similar, similar to what
has previously been reported for
diabetic
retinopathy and
diabetic
nephropathy. Diabetes Care February 2006.
Other causes for
neuropathy
Besides diabetes, neuropathies may also occur due to the following
reasons: autoimmune and inflammatory, toxic, neuropathies associated with plasma
cell dyscrasias, and paraneoplastic neuropathies.
Emails
Q. Could natural supplements offer a natural cure for diabetic neuropathy?
A. It's hard to say. Perhaps if caught in the early
stages, natural supplements, along with a strict diet and blood sugar control
could reverse the condition and offer a diabetic neuropathy cure or healing, but
there's still much to be learned.
Q. Why does diabetic neuropathy cause more problems in the
foot as opposed to the hand?
A. The answer is simple. The lower extremity is longer
than the upper extremities, and hence nerves to the feet are longer since they
need to reach from the spinal cord to the tip of the toe of the foot. When
peripheral diabetic neuropathy occurs, the feet are the first to suffer the
damage.
I found your information on SAM-e pills quite interesting. I have been taking 200 mg of SAM-e twice daily for several months. I have found it to boost my energy level and diminishing my mild depression. I note you connect SAM-e with repair of myelin sheath of nerve endings which fascinates me. I have "idiopathic small fiber peripheral neuropathy" - all tests for usual causes of peripheral neuropathy negative. I am otherwise a fairly healthy 74-year-old male (ran the Comcast Marathon in 2002). I am experiencing progressive numbness, which started with tingling of the soles of both feet in year 2000. Now the tingling/numbness has progressed to encompass my entire body. Numb scalp, numb face, fingers, hands, forearms, feet, legs, thighs, buttocks. EMGs (three of them over three years) show little or no muscle degeneration, just mild degeneration of nerve endings (myelin sheath). Now if SAM-e builds myelin sheath, shouldn't my taking 400 mg daily (empty stomach am and pm) have had some effect at reversing the degeneration of myelin sheath and restoring feeling? Should I combine the SAM-e with B-complex vitamins and other supplements? Should I increase dosage of SAM-e? I have been tested regularly and the results always show no vitamin deficiencies over the past six years. I follow quasi-vegetarian diet, no dairy, very little sugar, no coffee, no alcohol, no smoking, no white starches, no junk food. Mainly fresh fruits and vegetables, nuts and beans, some salmon, sardines, catfish, and chicken breast (all baked or roasted, never fried). I am slightly overweight (199 pounds at 5 feet, 10 1/2 inches in height). I walk a lot daily, but have not been running regularly since 2002 because the long distance running seemed to have increased the numbness. MRIs (three of them) and many x-rays show no damage to spine, no central nerve problems. SAM-e has given me great energy, I have progressed from taking steps one at a time (due to unreliable knee joints) to running up the stairs without any pain. I am hoping SAM-e will rebuild my small fiber nerves and reverse the peripheral neuropathy.
I am suffering from diabetes since 1995. I am on
tablets. From Dec 2005 I had developed with Diabetic NEUROPATHY PROBLEM. MY
FAMILY doctor gave me Lyrica 75 MG. FROM JAN 2006 MY PENIS GETTING thinner
and when erection time my penis is having abnormal bend. Therefore my penis is
not straight to do intercourse. I have a difficulty to do the intercourse. Do
you thing this problem is due to the diabetic neuropathy?
This is something to ask your personal doctor.
I am a 58 yr old female who was recently diagnosis with
diabetic neuropathy poor circulation (burning
feet, tingling and coldness on bottom
of feet not all the time). I work in the medical industry and I don't want to
take prescribed medication I rather take supplements. Presently I am taking
Vit-B12 , omega, flaxseed I keep myself active by walking 3 miles daily do
Pilates / Yoga not as often, always on top of the foods I eat. I have been
reading into other type of supplements that would help for patients that have
diabetes. I came across your website and the supplements that others recommended
you have them on the Diet Rx pill. My question is, will this supplement also
help the neuropathy or is there another supplement that would help.
Diet Rx has excellent antioxidant herbs and nutrients, including
acetyl-l carnitine and alpha lipoic acid that may help diabetic neuropathy but
we can't say since, as of December 2009, we don't have any reports from users of
this product regarding diabetic neuropathy. However, when people eat less, their
blood sugar is not as high and perhaps, over the long run, this could help blood
sugar control and better nerve sensation. You can discuss with your doctor other
options listed on this page.
I have
done some extensive research online on alpha lipoic acid. My father of 64 years
old has type 2 diabetes and for the past year has tried all kinds of
prescription drugs with no success (Lyrica, Cymbalta, Neurontin, Topamax, Elavil).
I found a treatment called the "Rebuilder" that uses a TENS setting to help
rebuild the nerves. While this machine was working great for my father for a
while, the cold sensation and tingling in his feet has slowly returned. He tried
using a topical cream called Zostrix but that wasn't too helpful either. He
maintains his blood sugar levels between 120-140 daily and exercises three to
four times a week. I guess what I am trying to get at is that I feel there must
be some alternative (more natural) treatment for the symptoms and possibly a
slow yet successful remedy with time. I have been reading on the benefits of
Alpha Lipoic Acid, Acetyl- L Carnitine, Ginkgo Biloba, Magnesium, Vitamin B
Complex, Evening Primrose Oil, Chromium and other numerous vitamins / minerals.
They all offer numerous benefits for diabetic neuropathy form what I have
researched online but when it comes down to it, how do you know which ones
exactly to take and/or which ones to combine? And if taken, how many milligrams
are safe to combine for each one? I know that obviously my father should not
take each and every one of these supplements at the same time and should also
consult his endocrinologist. However, we have had little to no luck when asking
his physicians on natural supplements. Therefore, I know you can not give out
personal advice due to liability, but if you could at least recommend what you
yourself would try and how much you would take of it if you were to have
diabetic neuropathy? Seeing my father suffer with the pain is very frustrating
and devastating to our entire family and we feel helpless because we can't stand
to see him suffer and lose hope the way he is doing thus far. I can only imagine
what someone with diabetic neuropathy must go through and by just seeing on a
daily basis what he has to endure, it really is heartbreaking. We know that
there is no cure for this but at least if you could provide some information on
successful treatments, again, my family and I would be ever so grateful!
I can understand the frustration and pain trying to deal with
this difficult condition. Unfortunately, as in most medical conditions, research
with natural supplements is limited and there are no easy answers. Alpha lipoic
acid is the most studied nutrient in terms of treating diabetic neuropathy, but
the ideal dosage is yet to be determined. Benefits have to be balanced with the
potential side effects. It is probably a good idea to use one supplement at a
time for a few weeks to know how it works by itself. There is a wide range of
individual response to supplements, and combinations of supplements, so it is
not easy to give precise dosages. Some people get benefits or side effects from
a dosage that could be a quarter or less compared to another person. The best
way to know is through trial and error.
I am a diabetic for 3 years along with diabetic Impotence,
and neuropathy. I just developed pins and needles in my legs and feet. Not
really painful yet, just very annoying (I cannot sleep a full night). I just
wanted your opinion on the chances of these complications reversing themselves
if I continue to have normal blood sugars for a long term duration. Can
peripheral nerves heal? Can autonomic nerves heal? Can these nerves heal or get
better without taking any supplements? I read on your website that taking
certain supplements can assist in helping with pain and ever regenerate some
nerves.
It's impossible to predict in any one case what the future holds,
but lifestyle changes, diet, superfoods, and the use of nutrients could
potentially reverse the severity of the nerve damage.